EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors

Taito Fukushima iD, Satoshi Kobayashi iD, Makoto Ueno

Japanese Journal of Clinical Oncology · 04.09.2024 · 54 (9) · 949-958

DOI: 10.1093/jjco/hyae067 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 20.05.2024. Verfasst von Taito Fukushima und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have revolutionized cancer treatment by targeting the cytotoxic T lymphocyte antigen-4 and programmed death-1/ligand-1. Although immune checkpoint inhibitors show promising therapeutic efficacy, they often cause immune-related adverse events. Immune-related adverse events differ from the side effects of conventional chemotherapy and require vigilant monitoring. These events predominantly affect organs, such as the colon, liver, lungs, pituitary gland, thyroid and skin, with rare cases affecting the heart, nervous system and other tissues. As immune-related adverse events result from immune activation, indicating the reinvigoration of exhausted immune cells that attack both tumors and normal tissues, it is theoretically possible that immune-related adverse events may signal a better response to immune checkpoint inhibitor therapy. Recent retrospective studies have explored the link between immune-related adverse event development and clinical efficacy; however, the predictive value of immune-related adverse events in the immune checkpoint inhibitor response remains unclear. Additionally, studies have focused on immune-related adverse events, timing of onset and immunosuppressive treatments. This review focuses on pivotal studies of the association between immune-related adverse events and outcomes in patients treated with immune checkpoint inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansDrug-Related Side Effects and Adverse ReactionsTreatment Outcome

Stichwörter der Autor:innen

atezolizumabefficacyimmune checkpoint inhibitorsimmune-related adverse eventsipilimumabnivolumabpembrolizumab

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Taito Fukushima, Satoshi Kobayashi

Zitieren

APA

Fukushima, T., Kobayashi, S., & Ueno, M. (2024). The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 54(9), 949-958. https://doi.org/10.1093/jjco/hyae067

Vancouver

Fukushima T, Kobayashi S, Ueno M. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese Journal of Clinical Oncology. 2024;54(9):949-958. doi:10.1093/jjco/hyae067

BibTeX
@article{Fukushima2024,
  author = {Fukushima, Taito and Kobayashi, Satoshi and Ueno, Makoto},
  title = {The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  volume = {54},
  number = {9},
  pages = {949--958},
  doi = {10.1093/jjco/hyae067}
}
Kostenlos starten →